
Regeneron Drug Pricing Deal with Trump; Free Hearing Therapy Offered
Regeneron has entered into a drug pricing agreement with the Trump administration, committing to lower the cost of certain medications for U.S. consumers. Furthermore, the company announced it will offer its new gene therapy, Otarmeni, for free to eligible patients following its FDA approval. These deals are part of a broader effort by the administration to align U.S. drug pricing with international standards. The agreements also include a three-year exemption from certain tariffs. Otarmeni is a significant breakthrough treatment targeting a rare genetic cause of hearing loss.






















